LICENSE AGREEMENTLicense Agreement • May 3rd, 2017 • Heat Biologics, Inc. • Pharmaceutical preparations • Florida
This License Agreement (the "Agreement") is entered into and made effective the 11th day of July, 2008 (the "Effective Date") between UNIVERSITY OF MIAMI and its School of Medicine, whose principal place of business is at 1600 N.W. 10th Avenue, Miami, Florida 33136 (hereinafter referred to as "LICENSOR") and HEAT BIOLOGICS II, INC., a Delaware corporation, whose principal place of business is at Atlantic Center, 119 Washington Avenue, Suite 401, Miami Beach, FL 33139 (hereinafter referred to as "LICENSEE").
ASSIGNMENT AND ASSUMPTION AGREEMENT (UMC-I3I, UMF:-I391)Assignment and Assumption Agreement • May 3rd, 2017 • Heat Biologics, Inc. • Pharmaceutical preparations • Florida
ASS1GNMENT AND ASSUMPTION AGREEMENT (the “Agreement”), dated as of June 26, 2009, by and among HEAT BIOLOGICS, INC., a Delaware corporation (“HEAT BIOLOGICS”), HEAT BIOLOGICS II, INC., a Delaware corporation (“HEAT II”) and for the limited purpose set forth on the signature page hereto, the University of Miami, a Florida not-for-profit corporation (“UNI VERSITY”).
Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the...Cancer Research Grant Contract • May 3rd, 2017 • Heat Biologics, Inc. • Pharmaceutical preparations • Texas
This CANCER RESEARCH GRANT CONTRACT (“Contract”) is by and between the Cancer Prevention and Research Institute of Texas (“CPRIT”), hereinafter referred to as the “INSTITUTE”, acting through its Chief Executive Officer, and Pelican Therapeutics, hereinafter referred to as the “RECIPIENT”, acting through its authorized signing official.
PAYMENT AGREEMENTPayment Agreement • May 3rd, 2017 • Heat Biologics, Inc. • Pharmaceutical preparations • Florida
This agreement (the "Agreement") is made 19th day of December, 2012 (the "Effective Date"), by and between the University of Miami and its School of Medicine ("UNIVERSITY"), and Pelican Therapeutics, Inc. a Delaware corporation ("PELICAN") formerly known as Heat Biologics II, Inc. ("HEAT II").
ContractLicense Agreement • May 3rd, 2017 • Heat Biologics, Inc. • Pharmaceutical preparations
Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.
LICENSE AGREEMENTLicense Agreement • May 3rd, 2017 • Heat Biologics, Inc. • Pharmaceutical preparations • Florida
This License Agreement (the "Agreement") is entered into and made effective the 19th day of November, 2013 (the "Effective Date") between UNIVERSITY OF MIAMI and its School of Medicine, whose principal place of business is at 1951 NW 7th Avenue, Suite 110, Miami, Florida 33136 (hereinafter referred to as "MIAMI") and Pelican Therapeutics, Inc., a Delaware corporation, whose principal place of business is at 100 Europa Drive, Suite 420, Chapel Hill, NC 27517 (hereinafter referred to as "COMPANY").
ContractLicense Agreement • May 3rd, 2017 • Heat Biologics, Inc. • Pharmaceutical preparations
Portions herein identified by [*****] have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. A complete copy of this document has been filed separately with the Securities and Exchange Commission.
